tbuckley/cabot-search huggingface dataset:
Abstract 263: Therapeutic Potential of a Novel Necrosis Inhibitor in Myocardial Ischemia-reperfusion Injury
Authors: Hyun-Jai Cho, In-Chang Hwang, Ju-Young Kim, Hak Seung Lee, Jaewon Lee, Jonghanne Park, Han-Mo Yang, Yoo-Wook Kwon, Soon-Ha Kim, Hyo-Soo Kim
Journal: Circulation Research (2015)

Background: Reperfusion, although essential for salvage of ischemic myocardium, paradoxically causes a wide variety of injuries. Opening of mitochondrial permeability transition pore (mPTP) and Ca 2+ overload contribute to myocardial ischemia-reperfusion (I/R) injury. We aimed to investigate the protective role of a novel necrosis inhibitor (NecroX-7; NecX) against myocardial I/R injury, using in vitro and in vivo models. Methods and Results: In H9C2 rat cardiomyoblasts exposed to hypoxia-reoxygenation stress, the main mechanism of cell death was not apoptosis but necrosis, which was prevented mainly by NecX, the necrosis inhibitor, but not by Z-VAD-fmk, the apoptosis inhibitor. The protective effect of NecX was based on its potent ROS scavenging activity, especially on mitochondrial ROS which is one of the major inducers of mPTP opening. NecX preserved mitochondrial membrane potential, mitochondrial structure, through prevention of Ca 2+ influx and inhibition of the opening of mPTP. Inhibition of necrosis by NecX was accompanied by reduction of phospho-p38 MAPK and phospho-JNK, and decrease of HMGB1. Using Sprague-Dawley rats exposed to myocardial ischemia for 45 minutes followed by reperfusion, we compared therapeutic efficacies of NecX and Ciclosporin A (CsA) with 5% dextrose (control), each administrated 5 minutes before reperfusion. NecX markedly inhibited myocardial necrosis, reduced fibrotic area and attenuated the release of cardiac enzymes, compared to dextrose and CsA. Additionally, NecX preserved systolic function and prevented pathologic dilatory remodeling of left ventricle. Conclusion: The novel necrosis inhibitor has a significant protective effect against myocardial I/R injury, indicating that it is a promising candidate for cardioprotective adjunctive measure on top of reperfusion therapy. Clinical implication: We are trying to translate this experimental data into patients. A phase I clinical trial confirmed the safety profiles of NecX [NCT01737424] and a phase II trial for STEMI patients (NEXsteMI trial) is ongoing [NCT02070471].
CCR7 Chemokine Receptor-Inducible lnc-Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF-1α-Mediated Glycolysis
Authors: Juan Liu, Xiaomin Zhang, Kun Chen, Yujie Cheng, Shuxun Liu, Meng Xia, Yali Chen, Ha Zhu, Zhiqing Li, Xuetao Cao
Journal: Immunity (2019)
Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET)
Authors: Fang Wang, Chao Yang, Jianyan Long, Xinju Zhao, Wen Tang, Dongliang Zhang, Kunhao Bai, Zaiming Su, Bixia Gao, Hong Chu, Jinwei Wang, Xiaoyu Sun, Song Wang, Li Zuo, Yue Wang, Feng Yu, Haibo Wang, Luxia Zhang, Ming-Hui Zhao
Journal: Kidney International (2019)
Blepharoptosis due to Sarcoidosis-induced Horner Syndrome
Authors: Masahide Takeda, Kazuhiro Sato, Masaaki Sano, Sho Sakamoto, Yuka Izumiya, Naho Kumagai, Kazuhisa Sudo, Mariko Asano, Yuji Okuda, Katsutoshi Nakayama
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study
Authors: Tamar Berger, Yakir Moshe, Shilo Yaari, Ilana Hellmann, Adina Aviram, Pia Raanani, Ron Ram, Yishai Ofran, Ofir Wolach
Journal: Blood (2018)
Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia
Authors: Sarah Elsayed, Barry E. Storer, Bruno C. Medeiros, Mona Ahmed Asslan, Ylinne Lynch, Jennifer E. Nyland, Pamela S. Becker, Mary-Elizabeth M. Percival, Elihu H. Estey, Mohamed L. Sorror
Journal: Blood (2018)
Irreproducible results in preclinical cardiovascular research: opportunities in times of need
Authors: Karin R Sipido
Journal: Cardiovascular Research (2019)

A hot topicConcerns about the lack of reproducibility in science have become a mainstream topic 1 and were centre-stage of a well-attended session at the ESC congress in Munich. 2 In medical research, lack of reproducibility is a bottleneck in translation.In 2011, Bayer Healthcare examined 67 biomedical research studies and could reproduce the main results in only 5 of them. 3The problem is not limited to cardiovascular research, but given disappointment in translation of some very promising concepts, it is an urgent question.So what is behind this failure of reproducibility?Fraud, manipulation, sloppy science-or is there a fundamental issue in the nature of research to consider.
Abstract P004: Higher Socioeconomic Position Strengthens Intergenerational Transmission of Ideal Health Behaviors
Authors: Kaisla Komulainen, Murray Mittleman, Markus Jokela, Marko Elovainio, Tomi Laitinen, Katja Pahkala, Markus Juonala, Mika Kähönen, Olli Raitakari, Liisa Keltikangas-Järvinen, Laura Pulkki-Råback
Journal: Circulation (2018)

Introduction: Promoting ideal health behaviors is an objective of the AHA 2020 goals. We assessed the hypothesis that ideal health behaviors transmit from one generation to the next and that higher socioeconomic position (SEP) in parents and their adult offspring promotes intergenerational transmission of ideal health behaviors. Methods: Data were from the intergenerational Cardiovascular Risk in Young Finns Study. We included 1857 participants who had repeated measures of educational attainment (as a proxy for SEP) and smoking status, BMI, physical activity and diet recorded in 2001, 2007 and 2011. Parental educational attainment and health behaviors were collected in 1980. We categorized data on health behaviors as ideal vs non-ideal (1/0) using AHA definitions of ideal cardiovascular health. The number of ideal health behaviors (0 to 4) was treated as a continuous outcome. The number of parental heath behaviors (0 to 8; each parent contributing equally) was the primary exposure. Intergenerational associations and interactions with SEP were examined in linear multilevel regression with random intercepts applicable to longitudinal data, adjusting for sex, study year, age, single-parent family and parental education. Results: Participants were 55% women; in 2001, mean age was 31.1 (SD, 5.0) and mean number of ideal health behaviors 2.0 (SD, 1.1). Overall, the adjusted mean number of ideal health behaviors increased with the number of parental ideal health behaviors, from 1.7 (95% CI, 1.6-1.7) to 2.1 (95% CI, 2.0-2.2) among participants with parents in the lowest vs highest 20% of ideal health behaviors. The increments were greater for those with higher levels of education (interaction p=.004) or those whose parents had higher levels of education (p=.007) ( Figure ). Conclusions: In this prospective study, higher number of ideal health behaviors in parents was associated with higher number of ideal health behaviors in offspring. Higher SEP in either generation strengthened the protective intergenerational associations.
P088 Characterization of novel humanized IL-17 mouse preclinical platforms for the efficacy evaluation of anti-human IL17 therapeutics
Authors: E Christodoulou-Vafeiadou, L Ntari, K Kranidioti, MC Denis, N Karagianni, G Kollias
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Career situation of first and presenting author</h3> Post-doctoral fellow. <h3>Introduction</h3> As the IL17/IL23 axis has proven pathogenic for many inflammatory conditions like rheumatoid arthritis, psoriasis, IBD, multiple sclerosis (MS) and others, IL17 inhibition is an attractive target for the treatment of these diseases. Indeed, biologics targeting human IL17 (hIL17) have recently proven a successful treatment for psoriasis with similar therapeutics being currently under development for this and other diseases. <h3>Objectives</h3> To describe novel preclinical platforms based on a hIL17A transgenic mouse model for the efficacy evaluation of human therapeutics, targeting psoriasis and MS. <h3>Methods</h3> Human IL17A transgenic mice were generated using as transgene a 170 kb genomic DNA fragment comprising hIL17A intron exon sequences flanked by extended 5' and 3' regulatory regions. These mice were further crossed with IL17AKO<sup>1</sup> resulting in a mouse line (<b>TghIL17</b>) that exclusively expresses hIL17A. We standardized IMQ-induced psoriasis and MOG-induced Experimental Autoimmune Encephalomyelitis (EAE) induction protocols in these mice and characterized their response to anti hIL17 treatment. Disease severity was evaluated using established clinical and histopathological scoring scales. <h3>Results</h3> TghIL17 mice have no overt pathology, and express hIL17A upon induction. IMQ- induced psoriasis induction in TghIL17 mice resulted in the development of skin pathology characterized clinically by skin erythema, thickening and scaling and histopathologically by acanthosis, hyperkeratosis and lymphocytic infiltration. Treatment with secukinumab resulted in alleviation of both clinical and histopathological psoriasis hallmarks to levels comparable to those observed in the IL17KO mice. MOG-induced EAE in TghIL17 mice resulted in clinical symptoms comparable to the ones observed in WT mice that involved, at the peak of the disease, paraplegia with forelimb weakness or paralysis. Treatment of EAE-affected TghIL17 mice with secukinumab ameliorated the pathological findings to a level similar to the one observed in IL17KO mice. <h3>Conclusions</h3> TghIL17 mice upon induction develop pathologies similar to WT animals demonstrating that human IL17A efficiently replaces its mouse counterpart. Using these mice with standardized IMQ-induced psoriasis and MOG-induced EAE protocols we established and validateed with commercially approved anti-hIL17 biologics, preclinical platforms that allow the efficient and reproducible evaluation of anti-hIL17 therapeutics. <h3>Reference</h3> Nakae S, <i>et al</i>. Antigen-specific T cell sensitization is impaired in Il-17-deficient mice, causing suppression of allergic cellular and humoral responses. <i>Immunity</i> 2002. <h3>Disclosure of Interest</h3> None declared.
1993 ANNUAL MEETING OF THE HOUSE OF DELEGATES
Authors: John L. Clowe
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lassa outbreak: WHO warns of unusually rapid spread in Nigeria
Authors: Owen Dyer
Journal: BMJ (2019)

A Lassa fever outbreak in Nigeria and neighbouring nations has caused concern among World Health Organization officials about the speed of its spread.

Lassa virus is a haemorrhagic fever similar to Ebola that spikes every year in west Africa from December to April. Last year’s outbreak was unusually deadly, claiming 171 lives, and in the first weeks of 2019 the confirmed cases climbed even more quickly.

Six weeks into the outbreak the number …
Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
Authors: James A McKinnell, Jamie P Dwyer, George H Talbot, Lynn E Connolly, Ian Friedland, Alex Smith, Adrian M Jubb, Alisa W Serio, Kevin M Krause, George L Daikos
Journal: New England Journal of Medicine (2019)

Plazomicin for Severe Resistant Infection This report compared plazomicin with colistin for the treatment of severe (bloodstream or pneumonia) infection with carbapenem-resistant Enterobacteriaceae...
Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice
Authors: Elya A. Shamskhou, Michael J. Kratochvil, Mark E. Orcholski, Nadine Nagy, Gernot Kaber, Emily Steen, Swathi Balaji, Ke Yuan, Sundeep Keswani, Ben Danielson, Max Gao, Carlos Medina, Abinaya Nathan, Ananya Chakraborty, Paul L. Bollyky, Vinicio A. De Jesus Perez
Journal: Biomaterials (2019)
Vaccination after Allogenic Stem Cell Transplantation: Diminished Memory B Cell Response and High Number of Spontaneously IgG Secreting Plasmablasts
Authors: Hannes Tittlbach, Andrea Schneider, Corinna Buchstaller, Andreas Mayr, Ingrid Vasova, Wolf Roesler, Andreas Mackensen, Michael Mach, Thomas H Winkler, Julia Winkler
Journal: Blood (2018)
Bright sports, physical activity investments that work: implementing brain breaks in Malaysian primary schools
Authors: Garry Kuan, Hussein Rizal, Mawar Siti Hajar, Ming-Kai Chin, Magdalena Mo Ching Mok
Journal: British Journal of Sports Medicine (2019)

### Programme card

#### Settings

#### Target population

#### What modes/types/domains of physical activity does the programme promote?

#### Which of the seven best investments does the programme address?

#### What sectors does it involve?

#### What is special about this programme?

#### Key programme details and contacts

Although a child’s physical development is inseparable from his or her cognitive development, the Malaysian education system prioritises academic achievement over physical development. Malaysian children and adolescents engage in low levels of physical activity.1 As in many countries, there is a need to increase physical activity among Malay adolescent communities in Malaysia.

To achieve this, the Global Community Health2 (GCH) and HOPSports3 introduced Brain BreaksPhysical Activity Solutions …
F-BAR domain only protein 1 (FCHO1) deficiency is a novel cause of combined immune deficiency in human subjects
Authors: Enrica Calzoni, Craig D. Platt, Sevgi Keles, Hye Sun Kuehn, Sarah Beaussant-Cohen, Yu Zhang, Julia Pazmandi, Gaetana Lanzi, Francesca Pala, Azzeddine Tahiat, Hasibe Artac, Raul Jimenez Heredia, Jasmin Dmytrus, Ismail Reisli, Vedat Uygun, Dilara Uygun, Aysen Bingol, Erdem Basaran, Kamel Djenouhat, Nafissa Benhalla, Chafa Bendahmane, Melike Emiroglu, Tomas Kirchhausen, Mithun Pasham, Jennifer Jones, Jacqueline G. Wallace, Lixin Zheng, Bertrand Boisson, Fulvio Porta, Sergio D. Rosenzweig, Helen Su, Silvia Giliani, Michael Lenardo, Raif S. Geha, Kaan Boztug, Janet Chou, Luigi D. Notarangelo
Journal: Journal of Allergy and Clinical Immunology (2019)
B Cell Precursor Lymphoblastic Leukemia Patients with Good Treatment Response Have Low Levels of Erythroid Precursors
Authors: Barbora Vakrmanova, Michaela Novakova, Martina Vaskova, Iveta Janotová, Elena Vodickova, Monika Brüggemann, Eva Fronkova, Jan Trka, Jan Stary, Ondrej Hrusak, Ester Mejstrikova
Journal: Blood (2018)
SP0162 Capillaroscopic Versus Laser Doppler Analysis of the Microcirculation
Authors: A. Sulli
Journal: Annals of the Rheumatic Diseases (2015)

Capillaroscopy is an easy, non-invasive, well-accepted, and safe method to early diagnose and follow nailfold microangiopathy in systemic sclerosis (SSc), having also prospective prognostic value for internal organ involvement [1,2]. In particular, nailfold videocapillaroscopy (NVC) is able to qualitatively and quantitatively assess SSc microvascular damage, by either detecting the "Early", "Active" or "Late" pattern of microangiopathy, or calculating the microangiopathy evolution score (MES) [3,4]. Capillaroscopy is routinely used in clinical practice, and it has recently been included among ACR/EULAR classification criteria for SSc [5]. In contrast to capillaroscopy that allows a morphological study of microcirculation, Laser Doppler and laser speckle techniques are able to assess microvascular function at skin sites, and they have been used in SSc to detect and quantify blood perfusion, in particular at peripheral sites [6–8]. Among these techniques, laser Doppler flowmetry is a contact method able to measure blood flow at a single point, in particular at fingertips, while laser Doppler imaging and laser speckle are non-contact techniques able to measure blood perfusion in a large area. In particular, laser speckle contrast analysis in less time consuming compared to Laser Doppler techniques, and permits the evaluation of skin areas different from hands [9]. Negative correlations have been described between nailfold microangiopathy extent (assessed by either NVC patterns or MES) and blood perfusion values (assessed by the above reported laser techniques) in SSc patients, being the higher microangiopathy degree, the lower blood perfusion values [6–10]. Furthermore, a reduced vascular reactivity to heating has been detected in SSc patients compared to healthy subjects, and it was found progressively lower in SSc patients with either worst NVC pattern of microangiopathy or higher MES [6]. The combination of these imaging techniques allows an optimal investigation of microcirculation in SSc, and it is useful to monitor drug effect on SSc microvasculature [11,12]. <h3>References</h3> Cutolo M, et al. Nat Rev Rheumatol 2010; 6:578-87. Smith V, et al. J Rheumatol. 2013; 40:2023-8. Sulli A, et al. Arthritis Rheum. 2012; 64:821-5. Sulli A, et al. Ann Rheum Dis 2008; 67:885-7. van den Hoogen F, et al. Ann Rheum Dis. 2013; 72:1747-55. Cutolo M, et al. J Rheumatol 2010; 37:1174-80. Rosato E, et al. J Rheumatol. 2009; 36:2257-63. Ruaro B, Sulli A, et al. Ann Rheum Dis. 2014; 73:1181-5. Sulli A, et al. Ann Rheum Dis 2014; 73:2059-61. Sulli A, et al. Ann Rheum Dis. 2014; 73:247-51. Cutolo M, et al. J Rheumatol. 2014; 81:881-6. Cutolo M, et al. J Rheumatol. 2013; 40:40-5. <h3>Disclosure of Interest</h3> None declared
Review of US Medical School Finances, 1996-1997
Authors: R F Jones, J L Ganem, D J Williams, J Y Krakower
Journal: JAMA (1998)

Based on data from the Annual Medical School Questionnaire of the Liaison Committee on Medical Education, to which 100% of schools responded, the revenues that supported the programs and activities of the 125 accredited medical schools in the United States totaled $34897 million in 1996-1997. A large proportion (78.9%) of these revenues was derived from 3 sources: practice plans, grants and contracts, and hospital support. Both public and private medical schools, in aggregate, have continued to experience growth throughout the last decade but at a progressively slower rate, primarily because of a slowing in the growth of practice plan revenues. Federal revenues supporting research in public and private medical schools since 1992-1993 have grown at annualized, constant-dollar rates of 5.6% and 4%, respectively. Growth in state and local appropriations to public medical schools has tended to lag behind inflation. Growth in reported revenues from endowments that are used to support programs at private medical schools is on the rise. The aggregate numbers mask considerable variation among schools with regard to changes in financing. A small, but appreciable, number of schools have witnessed a constant-dollar decline in their total practice plan revenues since 1992-1993. The financial data reviewed in this report demonstrate the continued dependence of medical schools on faculty-generated sources of revenue and confirm the perception that medical schools, as a group, are experiencing constraints on the growth of their enterprises.
Abstract 2164: Impact of Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent on the Outcome of Patients with Sirolimus-Eluting Stent Failure: Multicenter Registry in Asia
Authors: Sunao Nakamura, Mizuki Hirose, Jang-Ho Bae, Yeo H Cahyadi, Wasan Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul
Journal: Circulation (2007)

Purpose: To evaluate the Sirolimus-eluting stent (SES) and Paclitaxel-eluting stent (PES) on the outcome of patients with SES failure (SES-F). Methods: A total of 520 patients with 609 SES-F lesions (male 74.8%, mean age 72.1 yrs, LMT 7.1%, LAD 47.6%, LCX 25.0%, RCA 16.2%, SVG 4.1%) were treated with SES (mean lesion length 26.1±12.6 mm, mean stent length 31.3±15.9mm) and PES (mean lesion length 28.3±12.2 mm, mean stent length 32.9±19.3 mm). We evaluate immediate and long-term clinical results by 6 and 12 months angiography. Results: The baseline clinical characteristics between 2 groups were similar. See table for clinical results. Conclusion: The use of SES and PES in patients with restenosis after SES implantation was safe with low complications. Patients treated with SES showed lesser rate of restenosis compared with PES.
Novartis Access: a small step towards increased access for non-communicable disease care
Authors: Imran Manji, Sonak D Pastakia
Journal: The Lancet Global Health (2019)

Pharmaceutical companies are often maligned for many of the limitations in medication access in low-income and middle-income countries. Furthermore, many of their efforts to support health-care delivery in these settings are viewed solely as efforts to improve public relations and are not typically subjected to the in-depth peer review that most health-care interventions receive before dissemination to the public. In The Lancet Global Health, Peter Rockers and colleagues1 present a necessary and timely evaluation of an industry-led initiative to improve medicine access, which helps to change this narrative and provides many lessons to others in the pharmaceutical industry who are embarking on similar access programmes.
Vaccination Coverage Among Children Aged 19–35 Months — United States, 2017
Authors: Holly A. Hill, Laurie D. Elam-Evans, David Yankey, James A. Singleton, Yoonjae Kang
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination by age 24 months against 14 potentially serious illnesses (1). CDC used data from the 2017 National Immunization Survey-Child (NIS-Child) to assess vaccination coverage at national, state, territorial, and selected local levels among children aged 19-35 months in the United States. Coverage remained high and stable overall, exceeding 90% for ≥3 doses of poliovirus vaccine, ≥1 dose of measles, mumps, and rubella vaccine (MMR), ≥3 doses of hepatitis B vaccine (HepB), and ≥1 dose of varicella vaccine. Although the proportion of children who received no vaccine doses by age 24 months was low, this proportion increased gradually from 0.9% for children born in 2011 to 1.3% for children born in 2015. Coverage was lower for most vaccines among uninsured children and those insured by Medicaid, compared with those having private health insurance, and for children living outside of metropolitan statistical areas* (MSAs), compared with those living in MSA principal cities. These disparities could be reduced with greater awareness and use of the Vaccines for Children† (VFC) program, eliminating missed opportunities to vaccinate children during visits to health care providers, and minimizing interruptions in health insurance coverage.